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Brugada syndrome (BS) was reported for the ﬁrst time in
1992 and is associated with an ST-segment elevation in the
right precordial leads in the absence of any demonstrable
structural heart disease, as well as with sudden cardiac death
due to ventricular ﬁbrillation (VF).1 A patent type 1 electro-
cardiogram (ECG) is diagnostic of BS and is characterized
by a coved ST-segment elevation of Z2 mm followed by a
negative T wave in 41 right precordial lead (V1 to V3) in
the presence or absence of a sodium channel–blocking agent,
and in conjunction with 1 of the following: documented VF,
polymorphic ventricular tachycardia (VT), a family history
of sudden cardiac death at o45 years of age, coved-type
ECGs in family members, inducibility of VT/VF with
programmed electrical stimulation, syncope, or nocturnal
agonal respiration.2 An autosomal dominant disease with
incomplete penetrance, BS has been linked to mutations in
SCN5A, the gene encoding the alpha subunit of the cardiac
sodium channel. Still, SCN5A mutations have been reported
in only approximately 20% of patients with BS diagnosed on
the basis of clinical criteria, suggesting that other genetic
defects or other disease mechanisms may give rise to this
clinical picture.3
Noninvasive ECG imaging reveals that the abnormal
electrophysiological substrate is localized in the right ven-
tricular outﬂow tract (RVOT). Both abnormal repolarization
and abnormal conduction are present in the substrate.2,3KEYWORDS Brugada syndrome; Biopsy; Right ventricular outﬂow tract; Radio-
frequency catheter ablation; Electrocardiography; Electrophysiology study
(Heart Rhythm Case Reports 2016;2:211–216)
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phenotype of BS has been suggested repeatedly but never
demonstrated conclusively. The relationships in BS between
the clinical manifestations, the presence of SCN5A gene
mutations, and structural heart disease are highly complex.
Frustaci et al4 used an optical microscope to observe
hypertrophy and vacuolization of cardiac myocytes in
endomyocardial biopsies of the septoapical region of the
right ventricle from 3 patients. This study suggests that right
ventricular biopsy is the more sensitive approach to identi-
fying structural heart disease in patients with a phenotype of
BS. In this regard, more studies need to be done to clarify the
mechanistic links between the electrical substrate in BS and
the presence of a structural substrate.
The aim of the present study was to investigate whether
concealed cardiac abnormalities are present in a patient
diagnosed with BS and whether there is a correlation
between functional analysis and possible ultrastructural
alterations. We report the results of an endomyocardial
biopsy, guided by voltage and electroanatomic mapping of
the RVOT, with transmission electron microscopy (TEM)
analysis and the correlation of these results with clinical,
electrophysiological, and ECG ﬁndings. The present results
shed new light on the pathophysiology of the disease and
may help to account for its arrhythmic manifestations.Case report
A 38-year-old white woman, a nurse who experienced
frequent syncopal episodes, was admitted to our hospital in
April 2014. At admission, a clinical and family history was
collected, and the patient underwent physical examination
and noninvasive studies that included 2-dimensional echo-
cardiography, tilt test, computed tomography of the brain,
electroencephalography, Holter monitoring, human immu-
nodeﬁciency virus testing, laboratory testing, myocardial
perfusion scan, and cardiac magnetic resonance imaging.
The study protocol was approved by the institutional ethics
committee. Systemic diseases, Chagas disease, drug abuse,pen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.12.001
KEY TEACHING POINTS
 Abnormal electrophysiological substrate is
localized in the right ventricular outﬂow tract.
Both abnormal depolarization and abnormal
conduction are present in the substrate.
 We investigated the hidden heart defects and the
correlation between functional analysis and
ultrastructural alterations present in a patient with
Brugada syndrome.
 We report the endomyocardial biopsy, guided for
voltage map of the right ventricular outﬂow tract,
with transmission electron microscopy analysis and
the correlation with clinical, electrophysiological,
and electrocardiographic ﬁndings.
 We report the cell damage and death, progressively
from a peripheral to a central, very low-
voltage area.
 We recognize 3 functional and ultrastructural areas
on the substrate: a central area of very low voltage,
another peripheral area of intermediate voltage,
and ﬁnally a more peripheral area of normal
features.
 Guided by systolic voltage electrograms (EGMs)
map and diastolic bipolar EGMs, we identify areas
that contained low-amplitude late potentials,
middiastolic EGMs, and presystolic Purkinje-type
potentials. All these areas were targets for
ablation.
Heart Rhythm Case Reports, Vol 2, No 3, May 2016212electrolyte imbalance, and echocardiographic abnormalities
of the heart valves, the right and left ventricular dimensions,
and contractility were excluded. The patient had no family
history of BS or sudden cardiac death, but we found an
asymptomatic 17-year-old daughter with an induced patent
type 1 ECG. The diagnosis of BS was suspected after we
documented a patent type 2 ECG with saddleback appear-
ance, with a high takeoff ST-segment elevation of 42 mm
followed by a biphasic T wave in either lead V1 or lead V2 in
the second intercostal space (ICS) and we also noted the
presence of end-QRS slurs in the DI and aVL leads, with a
J-point peak ofZ0.2 mV and ST segment descending in the
DI lead and horizontal in the aVL lead, corresponding to an
early repolarization. BS was deﬁnitively diagnosed when the
patent type 2 (saddleback) ECG was converted to type 1 after
challenge with a sodium-channel blocker (ﬂecainide 400 mg,
orally), in precordial lead V1 to V3 in the second ICS,
which was associated with a ﬁnal R wave of aVR of 3 mv,
prolonged QRS duration in V2 of 150 milliseconds
(Figure 1), and documented VF induced with programmed
electrical stimulation. The patient did not accept an implant-
able cardiac deﬁbrillator.After obtaining written informed consent, we performed
an electrophysiological study, electroanatomic and voltage
mapping, endomyocardial biopsy, and catheter ablation
procedure. The study was conducted with the patient in a
fasting, drug-free, and sedated state. Under ﬂuoroscopic
guidance, a 6F quadripolar catheter (St Jude Medical, St
Paul, MN) and a 7F deﬂectable decapolar catheter (Livewire
TC, St Jude Medical) were introduced into the His bundle
region and coronary sinus, respectively, via the femoral
veins. Detailed mapping was performed in the RVOT using a
7F Saﬁre quadripolar ablation catheter with an 8-mm distal
electrode, an embedded thermistor, and a deﬂectable tip
(St. Jude Medical). Endocardial potentials were ﬁltered to
recording frequencies of 30 to 500 Hz and recorded on a
computer system (Feas Electrónica AR, Córdoba, Argen-
tina). During the procedure, the baseline interval AH was
110 milliseconds, HV-DI was 60 milliseconds, HV-V2 was
40 milliseconds, QRS duration in DII was 90 milliseconds,
and QRS duration in V2 was 150 milliseconds (Figure 2A).
The protocol of programmed electrical stimulation from
RVOT was performed (2 drive and r3 extrastimuli from
RVOT). An S1-S2 interval was applied after 8 beats of drive
pacing at basic cycle lengths of 600 to 400 milliseconds. The
S1-S2 interval was decreased in 20-millisecond steps until
the effective refractory period of the right ventricle, which
was 180 milliseconds, was reached. During a stimulation in
which the S1S1 value was 600 milliseconds, the S1-S2
interval was 240 milliseconds, and the S2-S3 interval was
200 milliseconds, we induced VF that lasted 410 seconds
and required an electric shock. Premature ventricular com-
plexes (PVCs) with a left bundle branch block morphology,
inferior axis, transition of4V3, and transitional zone index
of 1 occurred repetitively before episodes of spontaneous VT
from the RVOT area and preceded diastolic electrograms
(EGMs) (Figures 2B and 2C). Electroanatomic and voltage
mapping of the right ventricular and RVOT endocardium
was performed with the EnSite NavX system (St. Jude
Medical) (Figure 2D). Bipolar signals were ﬁltered at 30 to
400Hz and displayed at 100 to 200 mm/s. We deﬁned 3
zones according to the voltage amplitude of systolic EGMs: a
central very low-voltage zone of o0.5mV, a peripheral
low-voltage zone of 0.5 to 1.5mV, and a normal voltage zone
of 41.5 mV (Figures 2D and 3). After accessing the right
internal jugular vein with a 7.2F 45-cm deﬂectable sheath
catheter (Attain deﬂectable catheter delivery system, Med-
tronic, Minneapolis, MN), we connected a bioptome [Jawz
Endomyocardical biopsy forceps (Argon Medical, Plano,
TX), 6F, length 50 cm] to the NavX system and obtained
endomyocardial biopsies of the 3 previously deﬁned areas,
guiding by electroanatomic and voltage maps. Samples were
ﬁxed in 4% glutaraldehyde and 0.1% sodium phosphate
(pH 7.4) for the TEM study, as was described previously.5
Guided by voltage EGMs map systolic, electroanatomic
map, and bipolar EGMs diastolic, we identiﬁed areas that
contained low-amplitude late potentials, middiastolic
EGMs, and presystolic Purkinje-type potentials of low
amplitude and high frequency preceding the QRS for 20 or
Figure 1 A: Twelve-lead electrocardiogram (ECG) tracings baseline: patent type 2 ECG (not diagnostic) displaying a PR interval of 200 milliseconds, QRS
axis of 01, QRS duration in V2 [fourth intercostal space (ICS)] of 120 milliseconds, QT/QTc of 360/383 milliseconds, the presence of an end-QRS slur with a
descending ST segment in DI and horizontal in aVL, and saddleback-type ST-segment elevation observed in V2 (second ICS). Shift of right precordial leads in
second higher ICSs does not reveal a type 1 patent ECG, but an increased saddleback-type ST-segment elevation is observed in V2. Note the presence of the
end-QRS slur in DI and aVL, with a J-point peakZ0.2 mV and descending ST segment in DI and horizontal in aVL (red arrows). B: Twelve-lead ECGs after
oral administration of 400 mg of ﬂecainide: In the third hour, the type 2 ECG is converted to the diagnostic type 1 patent ECG, which consists of a coved-type
ST-segment elevation, observed in V2 of the standard 12-lead ECG (fourth ICS) and in V1, V2, and V3 recorded from the second ICS. Depolarization
abnormalities are present as a prolonged PR interval of 210 milliseconds, QRS axis þ81, prolonged QRS duration in V2 of 150 milliseconds, and a high ﬁnal R
wave in aVR of 3 mm, consistent with right end conduction delay. Repolarization disorder can also be seen, with a prolonged QT/QTc interval of 420/481
milliseconds. Note the disappearance of the end-QRS slur in DI and aVL and the appearance of S waves and leveling ST segment (red arrows).
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by radiofrequency application through a team of IBIS (Irvine
Biomedical, Irvine, CA) with a 50-W power setting, a
temperature of 601C, and a total duration of 60 seconds
per application to conﬁrm the disappearance of the diastolic
EGMs and PVCs. Then, the same stimulation protocol used
previously to induce VF was applied. Until the ventricular
refractory period, VF was not induced.
The patient was followed up monthly with physical
examination, resting ECG, Holter monitoring, and
2-dimensional echocardiogram. The patient has not experi-
enced symptoms or arrhythmia, and the ECG has shown noevidence of a BS pattern during follow-up as of the time of
this publication.Discussion
Some studies have considered BS a heart disease charac-
terized by functional electrical abnormalities mainly at the
RVOT, without evident morphological abnormalities. The
presence of unfractionated systolic EGMs of low voltage in
the endocardium has been reported,6 although the research-
ers noted the greater magnitude of these potentials, which
were targets for ablation, in the epicardium, where they were
Figure 2 A: Baseline AH interval of 110 milliseconds, HV-DI of 60 milliseconds, and HV-V2 of 40 milliseconds; QRS duration in DII of 90 milliseconds and
QRS duration in V2 of 150 milliseconds, indicating slow conduction in the right ventricular outﬂow tract (RVOT). B: Note the presence of middiastolic
electrograms (EGMs) during sinus rhythm (red arrows). We identiﬁed areas that contained low-amplitude late potentials, corresponding to the anterior area of the
high RVOT on the voltage map, where a systolic low-voltage EGM can also be seen in the proximal ablator. C: Spontaneous ventricular tachycardia from the
RVOT and diastolic EGMs preceding the onset of the QRS complex can be seen (red arrows), which correspond to presystolic Purkinje-type potentials of low
amplitude and high frequency preceding the QRS for 20 or 30 milliseconds. D. Voltage and electroanatomical maps, and the 3 areas of different voltage.
HV-DI¼HV interval measured DI; HV-V2¼HV interval measured V2; RVOT-D¼ distal right ventricular outﬂow tract; RVOT-P¼ proximal right ventricular
outﬂow tract.
Heart Rhythm Case Reports, Vol 2, No 3, May 2016214very fractionated. Fractionated EGMs probably caused by
electrical activation of small bundles of tissue are a common
manifestation of increased coupling resistance following
separation of myocardial ﬁbers in the reentrant circuit. In
the present study, using electroanatomic mapping, voltage
mapping, and conventional bipolar electrophysiological
mapping of the endocardium, we observed regions of
unfractionated systolic EGMs of low voltage in the RVOT,
in agreement with the previous report. However, we also
recorded fractionated middiastolic potentials of low voltage
in the endocardium and presystolic Purkinje-type potentials,
as shown in Figures 2B and 2C, which were targeted for
ablation. The middiastolic potentials probably correspond to
depolarization of isthmuses or channels proximal to the exit
during electrical diastole, and the presystolic potentials may
correspond to phenomena of spontaneous depolarization of
some Purkinje cells or diseased cells of the myocardium, or
activity from reentry-circuit exit regions. Spatial electricalheterogeneity within the myocardium through different
genetically determined changes of diastolic potential
explains high electrical instability in these patients.7 Using
TEM to observe differences in comparison to the normal
zone, we found speciﬁc changes consisting of cytoplasmic
degeneration of myocytes, mitochondrial swelling, and
vacuolization, with cell damage and death progressively
increasing from a peripheral area (0.5–1.5 mV) to a central
very low-voltage area (o0.5 mV) (Figure 3). Our ﬁndings
suggest that the functional alterations are correlated with
ultrastructural changes. In this case, we detected no fat
replacement—typical of arrhythmogenic right ventricular
cardiomyopathy—no active lymphocytic myocarditis, and
no Chagas myocarditis; these entities may mimic the clinical
ﬁndings and ECG of BS.8 In our patient, who had some
mutations in the cardiac sodium channel, the TEM analysis
did not reveal apoptotic bodies, although apoptosis is a
pathogenic mechanism demonstrated in arrhythmogenic
Figure 3 Endocardial biopsy by transmission electron microscopy. Voltage and electroanatomical map of A: normal lower area of the right ventricular
outﬂow tract (voltageZ 1.5 mv), and B: Purkinje cell with abundant secretory vesicles in the normal lower area. Note that when approaching the pathological
area, cytoplasmic disorganization, vacuolization (*) and myoﬁbrillar remains in the adjacent cells were evident. C: Mitochondria showing normal crest,
lipofuscin deposits near the myocyte nucleus and myoﬁbrils with classic characteristics in normal lower area.D: Voltage and electroanatomical map of peripheral
area (voltage between 0.5 and 1.5 mv). E: Myoﬁbrillar and cellular remains in the peripheral area. F: Note the disappearance of the mitochondrial crests,
mitochondrial swelling, and myoﬁbrillar disorganization (*) in the same area.G: Voltage and electroanatomical map of central area (voltager 0.5 mv). Note the
bioptome connected to the navigation system. H: Strong vacuolization and cell destruction in the central area. I: Intense cytoplasmic disorganization,
vacuolization, and remains of myocardial ﬁbers (*) in the central area. lp ¼ lipofuscin deposits; mi ¼ mitochondria; mf ¼ myoﬁbrils; nu ¼ nucleus;
pc ¼ Purkinje cell. Scale bar: B 2.2 μm; C, F, I: 1.42 μm; E, H: 3.33 μm.
215Tauber et al Functional and Ultrastructural Substrate in Brugada Syndromeright ventricular cardiomyopathy, BS, and dilated cardiomy-
opathy.9,10 Interestingly, an ultrastructural study showed
mitochondrial swelling and loss of the crest (Figure 3). This
ﬁnding raises the possibility that complete loss of mitochon-
drial energy does not favor the development of apoptosis
but may lead to necrosis11 and to progressive tissue
damage. Heart function is highly dependent on oxidative
energy generated in mitochondria, primarily by fatty acidβ-oxidation, respiratory electron chain reactions, and oxida-
tive phosphorylation. Defects in mitochondrial structure and
function have been found in association with cardiovascular
diseases such as dilated and hypertrophic cardiomyopathy,
cardiac conduction defects and sudden death, and ischemic
and alcoholic cardiomyopathy, as well as myocarditis.
Whereas a subset of these mitochondrial abnormalities
has a deﬁned genetic alteration, others have not yet been
Heart Rhythm Case Reports, Vol 2, No 3, May 2016216characterized.11 Although no genetic analysis was conducted
in this study, the ultrastructural results with the functional
data suggest that we are in the presence of BS.
An arrhythmic event may occur when a sufﬁcient degree
of cell damage has been reached and resting potentials are
reduced, through a reentrant microcircuit or triggered activity
from cells that are damaged but have not yet died, which in
turn would explain the presence of diastolic EGMs, such as
those found in the area of peripheral lesion in this patient
(Figure 3). If resting potentials reach the threshold of
vulnerable epicardial potential, they could initiate a phenom-
enon of phase 2 reentry, whose existence was previously
demonstrated.12 We found Purkinje ﬁbers during the
TEM analysis, and some studies have shown that these
ﬁbers may be involved in the genesis of early-onset PVCs,
which can trigger VT or VF.7 These assumptions need to be
investigated.
Another aspect to consider is the correlation between
higher ST elevation in the upper right precordial leads during
the ﬂecainide test (second ICS) and the location of the area of
low voltage in the anterior aspect of the high RVOT, as can
be seen in the voltage map. We have observed this
correlation in other patients (unpublished data) in whom
the highest elevation of the ST segment was in the lower
right leads (fourth ICS), coinciding with the anterior region
of the RVOT in the voltage map. This suggests the ability of
an ECG to locate the area of low voltage.
Continuing with the analysis of the baseline ECG, our
patient presented an end-QRS slur with descending ST
segment in the DI lead and horizontal in the aVL lead,
which corresponds to an early repolarization, according to
the latest consensus.13 The changing end-QRS slur in DI and
aVL leads, by "s" waves during the ﬂecainide test, which
mainly corresponds to the vector 41 depolarization of the
right ventricle and RVOT, may be the expression of a higher
right end conduction delay on the lateral aspect of the RVOT
that is coincident with an R wave in aVR of 3 mm. Some
researchers have suggested that early repolarization with a
horizontal or downward-sloping ST segment is potentially
more serious, since most of the cases with idiopathic VF are
associated with this pattern. There is a consensus that the
pattern of end-QRS notching and slurring may, on occasion,
be due to late depolarization rather than early repolarization,
suggesting that the term “early repolarization” should be
replaced by “J waves.” In the case we report, the slur or “J
wave” could correspond to a delay of the depolarization in
the lateral aspect of the RVOT by slow driving, since the area
of the lesion extended to that place, as shown in Figure 3. If
so, it could be speculated that an early repolarization with a
patent type 1 or type 2 ECG of BS suggests the existence of
an area of more extensive injury in the RVOT and increased
arrhythmic risk.
Similar to those that have already been reported in other
studies, depolarization abnormalities were present in this
case; we observed a prolonged PR interval, prolonged
QRS width (120 milliseconds), high R wave in aVR,
and increased duration of the P wave.14 Whereas someresearchers who conducted functional studies argue the
existence of a superior bundle of the right branch to the
RVOT, which would be affected in BS and likely responsible
for the alteration of depolarization, which was called “right
end conduction delay” or “right superior fascicular block,” 14
others denied its existence.15 Interestingly, as shown in
Figure 3, we found Purkinje cells in the normal region of
the RVOT. In concordance with this ﬁnding, an ECG pattern
recorded during a ﬂecainide test corresponding to a right end
conduction delay has been shown in Figure 1. Based on this
fact, it is necessary to ask about the role of Purkinje cells in
the conduction delay in the RVOT.
Conclusion
To our knowledge these ﬁndings provide the ﬁrst evidence
of an association between ultrastructural and functional
alterations in the RVOT in BS and offer a rational approach
for ablation of this substrate.
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